Attorney General Jeff Sessions Makes New Disparaging Comments on Marijuana

At a press conference today Attorney General Jeff Sessions made new, and disparaging, comments on marijuana. “Most of you probably know I don’t think America is going to be a better place when more people of all ages and particularly young people start smoking pot,” Sessions told reporters today. “I believe it’s an unhealthy practice…

via Attorney General Jeff Sessions Makes New Disparaging Comments on Marijuana — TheJointBlog.com

Advertisements

Marijuana industry, angered by White House reversal, speaks out “It just defies logic”

The cannabis industry was rattled Thursday after White House Press Secretary Sean Spicer said he expects the Department of Justice to increase enforcement of federal laws prohibiting recreational pot, even in states where it’s already legal.

Along with the District of Columbia, eight states have legalized recreational use among adults, including California, Maine, Massachusetts, and Nevada just this past November. That means one in five American adults can smoke, vape, drink, or eat cannabis as they please under state law.

Meanwhile, over half of the nation’s states have legalized medical marijuana despite federal laws prohibiting its sale. The industry is estimated to be worth north of $6 billion and will hit $50 billion by 2026, according to Cowen & Co.

“Today’s news coming out of the administration regarding the adult use of cannabis is, of course, disappointing,” Derek Peterson, CEO of marijuana cultivator Terra Tech Corp., said Thursday in a statement. “We have hoped and still hope that the federal government will respect states’ rights in the same manner they have on several other issues.”

Spicer sought to distinguish the prospect of federal enforcement for medical, versus recreational, cannabis use, saying “there’s still a federal law that we need to abide by when it comes to recreational marijuana and other drugs of that nature.”

Spicer’s statements reanimated industry concern that first arose when Republican President Donald Trump’s short-list of potential attorney general nominees emerged. The final pick, former senator Jeff Sessions of Alabama, a Republican, has long opposed cannabis use, but is a major proponent of state’s rights.

In his mid-January confirmation hearing, Sessions said he wouldn’t “commit to never enforcing federal law” but added that “absolutely it’s a problem of resources for the federal government.” He said that if Congress felt marijuana possession should no longer be illegal, it “should pass a law.” Trump has similarly gone back and forth on the issue of legalization.

Read the rest of the article at the Source:  Marijuana industry, angered by White House reversal, speaks out “It just defies logic”

Indiana Legislature Passes Bill to Legalize Medical Use of CBD, Now Goes to Governor

Legislation to legalize the medical use of cannabidiol (CBD) has been approved by Indiana’s full legislature.

The measure was approved 98 to 0 by the state’s House of Representatives on Tuesday, following approval from the Senate. It now goes to Governor Eric Holcomb for consideration.

Under the proposed law, it would be legal for those with a seizure disorder to possess and use medicines that contain marijuana-derived CBD, given they receive a recommendation from a physician. Tinctures, oils and pills would all be allowed, given they contain little virtually no tetrahydrocannabinol (THC).

Advocates of medical cannabis praised the decision by the legislature to approve the measure, but say it doesn’t go nearly far enough; they wan t the law expanded to include more medical conditions, and to allow for full-plant cannabis use and not just CBD.

New Hampshire’s House Criminal Justice and Public Safety Committee has passed a bill to decriminalize cannabis and hash possession.

New Hampshire’s House Criminal Justice and Public Safety Committee has passed a bill to decriminalize cannabis and hash possession.

House Bill 640 was approved with an overwhelming 14 to 2 vote. The measure would decriminalize the possession of up to an ounce of cannabis, and up to five grams of hash, for those 21 and older.

If police do catch someone possessing cannabis or hash within those limits, it would be “a fine of $100 for a first offense under this paragraph, a fine of $200 for a second offense within three years of the first offense, or a fine of $350 for a third or subsequent offense within 3 years of 2 other offenses.” Under current law the possession of even a minuscule amount of cannabis is a misdemeanor punishable by up to a year in jail.

House Bill 640 is sponsored by a bipartisan, bicameral coalition of a dozen lawmakers including Representatives Robert Cushing (D), Keith Murphy (R), Frank Sapareto (R), William Pearson (D), Carol McGuire (R), Chuck Grassie (D), Daniel Eaton (D), Patricia Lovejoy (D), as well as Senators Martha Clark, John Reagan, Daniel Innis.

Last year New Hampshire’s full House of Representatives passed a similar bill with a 289 to 58 vote, but it failed to pass the Senate.

According to a WMUR Granite State Poll released July of last year, 61% of New Hampshire voters support legalizing cannabis.

The full text of House Bill 640 can be found by clicking here.

Source:  New Hampshire Committee Passes Bill to Decriminalize Cannabis and Hash appeared first on TheJointBlog.com.

After Months of Public and Legal Pressure, DEA Removes Marijuana Misinformation from Website

The Drug Enforcement Administration (DEA) has removed marijuana misinformation from their website following months of public and legal pressure.

After months of public pressure, and a legal request by the nonprofit medical cannabis advocacy group Americans for Safe Access, the DEA has removed factually inaccurate information about marijuana from their website.

As part of the legal request, Americans for Safe Access argued that there was over 25 incorrect statements on the DEA’s website about cannabis, which violates the Information Quality Act, which prohibits government agencies from providing false information to the public, and requires them to respond to requests for correction of information within 60 days.

“The DEA’s removal of these popular myths about cannabis from their website could mean the end of the Washington gridlock” said Steph Sherer, Executive Director of Americans for Safe Access. “This is a victory for medical cannabis patients across the nation, who rely on cannabis to treat serious illnesses. The federal government now admits that cannabis is not a gateway drug, and doesn’t cause long-term brain damage, or psychosis. While the fight to end stigma around cannabis is far from over, this is a big first step.”

Americans for Safe Access’ full legal request which brought forth this change can be found by clicking here.

 

New Cannabis Patch To Treat Fibromyalgia And Diabetic Nerve Pain Revealed

A company that specializes in the use of cannabis as a form of medication have come up with a revolutionary pain patch that can be used to treat diabetic nerve pain and symptoms of fibromyalgia. This could change the way cannabis is viewed in the medical world forever.

The new medications are designed to be administered as transdermal patches, which are basically adhesive patches that are stuck to the skin and release certain chemicals over time to help combat neurological nerve pain associated with diabetes and fibromyalgia. Using this medium means a controlled dose of the medication can be administered on a daily basis, with no negative side effects discovered so far.

Cannabis Science, the company who originally designed the patches, said:

“Promote healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive which will be containing high potency cannabinoid (CBD) extract that slowly enters into the bloodstream and then penetrates the central nervous system of the patient delivering the pain relief sought.”

CBD is the second most major cannabinoid contained in cannabis, the main one being THC. CBD has incredible pain relieving and anti-inflammatory properties and comes from a completely natural source with very few side effects, including the hallucinogenic effects commonly associated with THC.

Mr. Raymond C Dabney, CEO of Cannabis Science stated that:

“The development of these two new pharmaceutical medicinal applications are just the tip of the iceberg for what we see as the future for Cannabis Science. While we strive to increase our land capacity for growth and facilities to produce our own product to supply our scientists with proprietary materials to make these formulations, we are also busy researching more potential needs for Cannabis related medical applications and developing the methods for delivery of these medications.”

Fibromyalgia is thought to affect up to 10% of us, with a huge number of sufferers not yet diagnosed. Nerve neuropathy diabetic pain affects a large number of people worldwide, and this new treatment will be a massive step in the right direction towards limiting certain symptoms, and maybe even curing these illnesses for good.

Mr. Dabney concludes:

“As more states nationwide legislate for the legalization of cannabis and cannabis-derived medications, we here at Cannabis Science are focused on developing pharmaceutical formulations and applications to supply the huge growing demand expected over the coming few years.”


Source:  Live The Organic Dream – New Cannabis Patch To Treat Fibromyalgia And Diabetic Nerve Pain Revealed

Congressmen to launch Cannabis Caucus in 2017

It’s a joint political effort to pass marijuana reform

Two members of Congress from both sides of the political aisle are joining forces to create the Cannabis Caucus.

Reps. Dana Rohrabacher, R-Calif., and Earl Blumenauer, D-Ore., are creating a caucus in hopes of improving the odds to passing federal marijuana reform bills.

“There needs to be more strategy between us, those of us who are engaged in this. More of a long-term strategy,” Rohrabacher told DecodeDC . “[And] we need to have a vehicle in which people on the outside will be able to work through and sort of have a team effort from the inside and the outside.”

Rohrabacher says Rep. Thomas Massie, R-Ky., is likely to emerge as the spokesman for the caucus, which he said will begin meeting in January.

The caucus will be made up of members of Congress who see marijuana reform as an important issue and it will focus on a bipartisan effort to pass bills, Rohrabacher said. He did not name lawmakers he expects to join.

“We want to make the states’ rights issue the core of what we are doing,” Rohrabacher said, referring to the argument that states should be able to choose for how to regulate and classify marijuana. “Republicans don’t see this as something that their constituents want and they may not be positive towards legalization of marijuana. But with the states’ rights issue, that’s how we’ve won the necessary votes from the Republican side in order to win the battle.”

Rohrabacher and Blumenauer have been vocal champions for years of marijuana decriminalization and a state’s right to choose how to regulate the drug.

Rohrabacher has admitted in the past that he used marijuana to help with arthritis pain. He introduced the Respect State Marijuana Laws Act of 2015.

Blumenauer also visited many states this year, campaigning for ballot measures that would legalize medical marijuana or recreational marijuana for adults.

The congressman introduced the Medical Marijuana Research Act of 2016, a bi-partisan bill that aimed to “cut through the red tape” that currently makes it very hard for scientific researchers to obtain marijuana for clinical trials. Additionally, he co-sponsored the Marijuana Businesses Access to Banking Act of 2015, which would have allowed marijuana businesses to stop functioning in all-cash.

According to Blumenauer, the two biggest issues currently facing the marijuana industry are that companies aren’t fairly taxed because federal law won’t allow them to fully deduct their business taxes — and that cannabis businesses can’t work with banks. Currently marijuana companies have to be all-cash businesses largely thanks to marijuana’s classification as a Schedule I drug, which puts it in the same category as heroin.

“We’ve had the movement crest,” Blumenauer told DecodeDC. “Two hundred and fifty million people have access to medical marijuana, a quarter of the population has access to adult use. We’re watching an industry now where 60 percent believe marijuana should be legalized, and public opinion mirrors what happened at the ballot box.”

Marijuana currently is legal for adult recreational use in eight states and medical marijuana is legal in 28 states and Washington, D.C.

Blumenauer says he has hope that marijuana reform will become a stronger bi-partisan effort on Capitol Hill in 2017.

“People who have been ambivalent about this before, all of a sudden just inherited constituents who care deeply about it,” he said. “Florida just passed an initiative for medical marijuana which makes it the second largest marijuana market in the United States. All of a sudden there are lots of legislators who just had their constituents vote more strongly for marijuana than they did for them.”

Source:  Decode DC: Congressmen to launch Cannabis Caucus in 2017

Study: Marijuana Extract Associated With Improved Survival Rates In Glioma Patients

By NORML

Brain tumor patients treated with marijuana extracts have increased survival rates compared to those who go untreated; this is according to newly released research.

Twenty-one patients with recurrent glioblastoma multiforme and who were undergoing conventional anti-cancer treatment participated in the study. Patients received either a proprietary cannabis extract containing a combination of THC and CBD or a placebo.

“[P]atients with documented recurrent GBM treated with THC:CBD had an 83 percent one year survival rate compared with 53 percent for patients in the placebo cohort,” the company summarized in a press release. “Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group.”

The study’s findings replicate preclinical data demonstrating that the adjunctive use of cannabinoids with temozolomide may be associated with greater anti-cancer activity than the use of conventional therapy alone.

Glioblastoma multiforme is an especially aggressive form of cancer; only 28 percent of patients survive after one year and fewer than four percent surviving five years.